Business Context and Reporting Period
This Form 8-K Current Report was filed by Collegium Pharmaceutical, Inc. on April 6, 2022. The report discloses corporate governance changes, specifically the expansion of the Board of Directors and the appointment of a new director.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The only financial data disclosed relates to director compensation:
- Annual Cash Retainer: $50,000 (prorated based on appointment date).
- Restricted Stock Units (RSUs): Grant date value of $337,500 (representing an initial award plus 50% of the annual equity award).
Material Changes
The Board of Directors expanded its size from eight to nine members. Mr. Neil F. McFarlane, age 49, was appointed as a director effective April 6, 2022. His initial term expires at the annual meeting of shareholders on May 19, 2022.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, or management commentary regarding business operations. It notes that Mr. McFarlane entered into a standard indemnification agreement. The company confirmed there are no related party transactions involving Mr. McFarlane reportable under Item 404(a) of Regulation S-K and no family relationships with existing directors or officers.
Investor Verification Checklist
- Verify the vesting schedule for the $337,500 RSU grant (vests on the first anniversary of the grant date).
- Confirm the prorated cash retainer amount for the partial year of service.
- Review the full text of the indemnification agreement filed with the SEC.
- Check for any subsequent filings regarding the May 19, 2022, annual meeting of shareholders.